Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
from bseg site
There's been several shareholders that have enquired about the status of updating BSEG financials and removing Stop symbol on the OTC Pinksheet site.
BSEG has inputted all financial data and we are waiting on Accountants to complete our filings. They seem to take their own time on these matters.
During Covid, Big Screen's bookkeeper came down with Covid and decided not to work for awhile. We've had to find people to replace her during Covid. It's been a real challenge.
We are getting caught up now. And currently looking to hire an Interm CFO or Controller to fill this position. This will enable us to do our job of expanding the company.
The goal is to have financials updated and current by June 30 or sooner
Thank you for your understanding
from the forum
Posted 23/01
Will be sure to let everyone know once we have a date set. Upper management currently in the middle of a contract negotiation that is taking quite a bit of their time.
As soon as a date is set for a conference call/shareholder meeting, the company will announce
publicly in a press release.
Will keep everyone updated as to when and where.
Thank you
Sep 8, 2016 Quarterly Report - OTC PINK 2Q 2016 BALANCE SHEET & FOOTNOTES & STATEMENTS OF EQUITY & CASH FLOWS
Sep 8, 2016 Management Discussion and Analysis - OTC PINK 2q 2016 MANAGEMENTS' DISCUSSION AND ANALYSIS
http://www.otcmarkets.com/stock/DECN/filings
http://www.otcmarkets.com/stock/DECN/filings
Quarterly Report - OTC PINK 2Q 2016 BALANCE SHEET -- STATEMENTS OF EQUITY & CASH FLOWS & FOOTNOTES
Management Discussion and Analysis - OTC PINK 2Q 2016 MANAGEMENTS' DISCUSSION AND ANALYSIS
Supplemental Information - OTC PINK 2Q 2016 SUPPLEMENTAL DISCLOSURE INFORMATION
BEVERLY HILLS, CA--(Marketwired - January 06, 2016) - Moving into the New Year, Big Screen Entertainment Group (OTC PINK: BSEG) is pleased to announce that this past year, Big Screen Management laid the foundation for many new opportunities towards expansion, partnerships and co-productions for the benefit of the Company and its shareholders.
First, BSEG is excited to announce the formation of BSEG Holdings. The purpose of this company will be to oversee the development, structuring and financing of numerous subsidiaries under the Big Screen Brand.
The production, film, television, commercial service division as well as the distribution division will now be under Big Screen Pictures. Big Screen Pictures has been actively developing new projects with several production companies in China as well as Red Granite Pictures in the US. "We are continuing on expanding our distribution and production into the Asian market place under its partner Fairfax Entertainment Group," stated BSEG Chairman and CEO of Fairfax, Dr. Jimmy Jiang.
BSEG Holdings is focused on expanding into education, including building a university for foreign exchange students, known as American Big Screen Education.
BSEG Holdings is also overseeing Big Screen Media, focusing on advertising, web-series, film events and festivals, marketing partnerships, expansion as well as an international New Media company.
Big Screen Merchandising is another new subsidiary formed under the BSEG Holdings brand. Big Screen Merchandising is focusing on generating a multitude of revenue producing activities from artist skin-care's products to fashion to new technology, apps and partnerships with companies in China and the US. "BSEG Holdings has formed two new alliances with manufacturing companies to date," stated BSEG Chairman, Dr. Jiang.
Additionally, BSEG Holdings will have a subsidiary focused on the capital markets side of the company, dedicated to meeting new investors and potential business partnerships both in the US and abroad.
"Our long term goal has been and remains the same: to move the company from its current listing on the Pink Sheets up the tiers and eventually to NASDAQ. In order to achieve management goals and visions for the Company, we have been and will continue on launching numerous revenue generating ventures," stated BSEG CEO, Kimberley Kates.
"Through strong entertainment industry growth factors in the rapidly expanding Asian entertainment markets, BSEG Holdings aims to grow its presence in entertainment and other media technologies both domestically and globally," said Dr. Jiang in a recent Board Meeting held with Management.
A new website with more details of the BSEG Holdings various subsidiaries will be launched this January.
OTHER BSEG NEWS:
BSEG Management wishes to congratulate its CEO, Kimberley Kates on her Golden Film Award for Best Producer, as well as The Deka Bros. for their Visual Effects Golden Film Award and Dr. Bruce Lee for Best Composer for their work on BSEG's "Mosquito Man," being released on January 12, 2016.
Lastly, financial reports will be posted to OTC Markets by January 15, 2016.
Decision Diagnostics Completes Investment in Korean R+D and Contract Manufacturing Partner
LOS ANGELES, CA / ACCESSWIRE / June 15, 2015 / Decision Diagnostics Corp. (PINKSHEETS: DECN), the manufacturer, quality plan administrator and the exclusive worldwide sales, service and regulatory processes agent for the popular GenStrip(TM) 50, the FDA-cleared Green Alternative Glucose Test Strip, specifically designed to work with the market leading Johnson & Johnson's LifeScan OneTouch Ultra family of glucose testing meters, the most popular meter worldwide for diabetic use, announced today that on May 29, 2015, we completed an investment in special manufacturing equipment in Korea at the facilities of the company's second contract manufacturer.
This specialty manufacturing equipment, which will serve our product, business and growth interests now and into the future, was memorialized in a follow-up investment agreement with Alpha Capital Anstalt ("Alpha") on June 4, 2015, whereby Alpha purchased an 18-month, 15% OID derivative instrument in the amount of $275,000 from the company. Terms of this agreement with Alpha, call for a 15% OID with both redemption and conversion features and Warrants (for follow-on investment). The conversion feature set the conversion price as the closing price of the company's common stock on May 29, 2015 less $.025.
Forward-Looking Statements:
This release contains the Company's forward-looking statements which are or may be based on management's current expectations and assumptions as of June 14, 2015, regarding the Company's business and performance, its prospects, current factors, the economy and other future conditions and forecasts of future events, circumstances and results.
Contact:
Decision Diagnostics Corp.
Keith Berman
(805) 446-2973
info@decisiondiagnostics.com
Jan 07, 2015
OTC Disclosure & News Service
-
Big Screen Entertainment Group Announces First Production of the Year
HOLLYWOOD, CA--(Marketwired - Jan 7, 2015) - As part of its initiative to extend its global brand and a new franchise into new lines of business internationally and with China, Big Screen Entertainment Group (OTC PINK: BSEG), an emerging global content leader with China, will begin its first of a five part series of films, SNOW WHITE CHRONICLES.
SNOW WHITE CHRONICLES, Part One - Adventure in China, has already received partial financing. The film will be a co-production with a leading Chinese based production company. International and US sales are being handled by Red Granite International.
The movie will feature several stars from Europe, China and the US. Snow White is scheduled to begin filming in 2015 with a theatrical release in China and Internationally for 2016. BSEG will co-produce with its Chinese partners.
"We're committed to extending the BSEG brand into exciting new businesses that create opportunities with the properties we are creating through theme parks and other arenas. At the same time we plan on delivering financial benefits to Big Screen Entertainment Group. China's box office grew 36% in 2014 to $4.6 billion," said BSEG CEO Kimberley Kates.
"We're thrilled to launch this global co-production bringing in both Chinese elements to a well known brand told in a unique way that entertains fans worldwide."
Kates also said, as part of BSEG's commitment to expand its brand, BSEG plans on expanding into merchandising and other financial benefits such as theme parks and other location-based entertainment attractions in China. Ms. Kates leaves this month to begin location scouting as well as meetings on various other projects for the company.\
Movie also sold out on Rakuten and Familyvideo
From Facebook:
#BSEG new release YOU CAN'T KILL STEPHEN KING is selling like hotcakes on DVD. And SINGULARITY PRINCIPLE is rocking it on VOD. Good month for our films! yaaay
Big Screen Entertainment Group Sets Release Date for New Film - "YOU CAN'T KILL STEPHEN KING"
HOLLYWOOD, CA--(Marketwired - Nov 10, 2014) - Big Screen Entertainment Group (PINKSHEETS: BSEG) is excited to announce the release of YOU CAN'T KILL STEPHEN KING on DVD December 9th.
YOU CAN'T KILL STEPHEN KING is a comedy horror and fan tribute to the work of the great author. The film contains elements from across Mr. King's written repertoire as well as references to many of the film adaptations. "Die hard fans will be hard pressed to recognize them all," said director Monroe Mann.
YOU CAN'T KILL STEPHEN KING has been receiving favorable reviews from critics who have described the film as having "ingenious plot, good fun with a wry sense of humor."
Big Screen's DVD distributor has had to run more DVDs than anticipated on YOU CAN'T KILL STEPHEN KING as orders are higher than first predicted.
Big Screen's spectacular romantic vampire film, CRIMSON WINTER, is now available on DVD.
SINGULARITY PRINCIPLE will be coming to DVD in January. Starring John Diehl (STARGATE, JURASSIC PARK III) and William B. Davis (THE X FILES), SINGULARITY PRINCIPLE follows a scientist as he tries to replicate an experiment to create a parallel universe and explores the theory of the God Particle. The film was shot by renowned physicist Dr. David Deranian in a special $300 million lab in Northern Canada.
OTHER BSEG NEWS:
BSEG's Q2 financials to be released this week;
Announcement regarding the $100 million film fund and a deal on one of the first films through the fund;
Details on a new film franchise and co-production with China to be released soon.
DECN's Subsidiary Initiates First in Industry Social Media Marketing Campaign for Genstrip50
Nov 05, 2014 (ACCESSWIRE via COMTEX) -- 900,000 Current Users of J&J Lifescan Ultra Products Targeted With Expected Generation of $75 Million Annually at 20% EBITA
LOS ANGELES, CA / ACCESSWIRE / November 5, 2014 / Decision Diagnostics Corp. (OTC: DECN), the manufacturer, quality plan administrator and the exclusive worldwide sales, service and regulatory processes agent for the popular GenStrip(TM) 50, the unique Green Glucose Test Strip, specifically designed to work with the Johnson & Johnson's (NYSE: JNJ) LifeScan Ultra family of glucose testing meters, announced today that their Pharma Tech subsidiary has engaged the services of ATM Digital Branding, LLC ("ATM"), a Dallas, TX based, industry leading, digital marketing and branding agency. ATM uses a proprietary process called Attract, Talk and Monetize to leverage digital tools such as social media, social advertising, pay per click advertising, smart website design and Web search engine optimization, to communicate information regarding its blood glucose test strip, Genstrip50, to the traditional diabetic market.
The vast majority of diabetics still purchase their daily blood glucose test strips from brick & mortal retail pharmacies. A minor migration has gravitated to on-line purchases, but nearly 3 million of the prospective GenStrip50 users still visit the local pharmacy or mass merchandiser for their monthly supply. This traditional purchase encounter is likely a function of a hesitation towards an online medical purchase. However, diabetics regularly confer through various social media channels to learn and share disease information, treatment options and, most importantly, to exchange life experiences arising from their physical challenges. The Pharma Tech digital communication program has begun to capitalize on those dialogs and join them to restructure their traditional diabetic buying process.
Keith Berman, CFO and Principal Executive of Decision Diagnostics stated that, "There exists an extensive user base of current diabetics, almost virtual unknowns to the diabetic supplies distribution networks, that would welcome the opportunity to forego their regular trip to purchase their box of test strips at the local retailer. We will assist them in arriving at the obvious decision to take advantage of the dramatic advantages of an on-line GenStrip50 purchase. This ATM Branding social media campaign has already engaged diabetic digital conversations to influence diabeticsmaking their first purchase through a coupon and a discount first purchase program. Once the overwhelming benefits of that purchase are experienced, that customer will never return to the store for their blood glucose test strip."
Social Media marketing directly targets those conversations and engages the diabetics in real time. The communication tools employed by the company's various interactive platforms will make GenStrip50 accessible to those already curious about an alternative acquisition process and visible to those who have never before considered purchase alternatives. Since social media is fundamentally a conversation between people sharing information about similar interests, engaging in those conversations will create awareness of product's on-line availability, trust in the reliability of that vehicle and the dramatic cost savings associated with its purchase.
Mr. Berman concluded by saying that, "This program has just recently begun and yet we are already seeing a significant impact on our sales, follow-up inquiries about Genstrip50 and on-line chatter. We anticipate a universe, where we are the only participant, generating about $75,000,000 in annual revenues and $15 million in annual profits, all low hanging fruit, available for us to seize through this social media campaign. We intend to capture all of it."
Big Screen Entertainment Group The Marmignon brothers are the sons of top CEO of Auchan in France. They have worked with BSEG for over a year in setting up our new division which they will manage. Very pleased to have them aboard.
BSEG proud to announce our European division run by Corentin and Clotaire Marmignon - Team Europe
Big Entertainment International
Media/News/Publishing
(from facebook)
Ms Kimberley Kates honorary member of Chinese Culture Organization http://www.cccosite.org/en/aboutus/council
Big Screen is currently working with some of the best and brightest from the Chinese markets. We're looking forward to a great future with both Hollywood/Chinese Co-Productions.
http://www.hollywoodreporter.com/news/china-box-office-track-5-730194
This morning
David Defeats Goliath (Again), DECN and Pharma Tech Solutions Awarded Victory Over Johnson & Johnson Lifescan in USPTO Final Ruling
Major Claims in J&J Lifescan Patent 7,250,105 Ruled "Unpatentable" by Three Judge USPTO Panel
LOS ANGELES, CA, Aug 11, 2014 (Marketwired via COMTEX) -- Decision Diagnostics Corp. (PINKSHEETS: DECN), the manufacturer of an exclusive worldwide sales, service and regulatory processes agent for its popular GenStrip(TM) glucose test strip, specifically designed to work with Johnson & Johnson's LifeScan Ultra family of glucose testing meters, announced today that on August 6, 2014, the United States Patent and Trademark Office, Patent Trial and Appeal Board has sustained, in a final ruling, the company's challenge to Johnson & Johnson Lifescan's Patent 7,250,105, specifically "claims 1-3 ... for obviousness, ... by a preponderance of the evidence." These three claims are used by J&J Lifescan as the foundation of their patent infringement lawsuit against DECN and Pharma Tech. The USPTO Judge Panel has ruled these claims as "unpatentable."
The August 6, 2014 ruling marks the third ruling by a higher court on this same J&J Lifescan Patent. Previously in August 2013, in a preliminary ruling, the same USPTO three judge panel determined "that Pharmatech has demonstrated that there is a reasonable likelihood of its proving the unpatentability of claims 1-3 of the '105 patent by a preponderance of the evidence.' In November 2013 the Federal Circuit Court, reversed an earlier ruling made in late March 2013 by a District Court judge in Northern California, and ruled that the J&J Lifescan patent rights (under patent 7,250,105) were subject to the doctrine of patent exhaustion.
Keith Berman, Principal Executive Officer of Decision Diagnostics, commented, "The USPTO Patent Trial and Appeal Board's ruling along with the November 2013 Circuit Court's ruling, has put to rest significant parts of J&J Lifescan's lawsuit. We are delighted with this most recent ruling. We plan to continue our march forward without the distractions of frivolous lawsuits that have been used to create barriers of entry to a free market. By all estimation, August 6, 2014 and November 4, 2013 are seminal days in DECN's history. We will have more to discuss about other aspects of this ruling and ancillary issues in the coming days."
News Out: Congrats to our CEO, Kimberley Kates and her continued relations with China, also thanks to our new Co-Chairman Jimmy Jiang.
http://www.streetinsider.com/Press+Releases/Big+Screen+Entertainment+CEO+Invited+to+Judge+for+Biggest+Talent+Show+in+China+--+Deadline+Extended+for+Entries/9672724.html
Decision Diagnostics Announces Agreement for the Funding of Its Prosecution of Anti-Trust and False Advertising Suits Against Division of Johnson & Johnson
Fresh From the Court Ruling on Its GenStrip Product, DECN Pivots From Defense to Offense to Prosecute Johnson & Johnson in Two Countersuits DECN to Seek Triple Damages and Readies Attack on $12.7M Court Ordered Bond
LOS ANGELES, CA, Feb 14, 2014 (Marketwired via COMTEX) -- Decision Diagnostics Corp. (OTCQB: DECN), the exclusive worldwide sales, service and regulatory processes agent for the popular Shasta GenStrip(TM), the unique Green Glucose Test Strip, specifically designed to work with the Johnson & Johnson's LifeScan Ultra family of glucose testing meters, today announced that that the Company has executed a Terms Agreement with a major east coast based litigation prosecution fund for the financing of the prosecution of DECN's countersuits brought against LifeScan, Inc., a division of Johnson and Johnson, Inc. DECN has asserted claims for anti-trust violations and false advertising.
"The antitrust prosecution, if successful, carries with it a possible award of triple damages," said Keith Berman, DECN's Principal Executive Officer and the GenStrip Program Director. Mr. Berman further observed, "In our case, we are pursuing two prizes simultaneously, first the prosecution of our anti-trust and false advertising claims for J&J's anti-competitive behavior throughout our dispute, and secondly, we will assemble our arguments and begin a process of collecting on the damages we have suffered as the result of the J&J patent litigation on which the Court of Appeals for the Federal Circuit has ruled favorably for DECN. This higher court ruling offers DECN an opportunity to begin prosecution efforts, an upcoming attack as some have called it, on the $12.7 million court ordered litigation bond. Our litigation financing partner has put up a substantial pool of capital specifically to assist us in achieving significant positive outcomes for these prosecutions."
In the meantime, the company reminds shareholders and all interested parties that it is currently airing its GenStrip commercial video titled, "A Winter Patchwork" in every region of the country, and has secured play times on all cable outlets that will televise the 2014 Winter Olympics. The company's media schedule calls for almost 13,000 total 30 second buys with the commercial playing all hours of the day except for late morning and dinner hours. The extremely popular video is available for viewing at: http://shastagenstrip.com/winter_ad.html or
I believe China Film Group Corporation is the sole importer and exporter. Big Screen signed a deal with them.
Decision Diagnostics On Track For Growth and Increased Revenues
Nov 07, 2013 (ACCESSWIRE via COMTEX) -- COLORADO, Nov. 7, 2013 - The Shasta GenStrip blood glucose monitoring test strip for in-home use received FDA approval on November 30, 2012. Decision Diagnostics Corp. (OTCBB: DECN) has been fighting a battle to bring the Shasta GenStrip to market ever since and DECN's management is now realizing the fruits of their labor.
Decision Diagnostics is the exclusive worldwide sales, service and regulatory process agent for Shasta GenStrip, which is a blood glucose test strip designed to work with Johnson & Johnson's (J&J) market leading LifeScan Ultra family of glucose test meters. What makes the opportunity unique is that Decision Diagnostics management has said their GenStrip can be up to 50% less expensive than competitors' products, which is expected to drive strong demand for the product. The rollout of GenStrip has been delayed by legal efforts by J&J as well as constraints on capital to grow manufacturing volume for expected demand. Over the last two weeks DECN's management has seen many of the legal and financial issues that prevented the product from reaching consumers fade significantly.
In March 2013 Decision Diagnostics was issued a Preliminary Injunction from a District Court Judge in Northern California essentially banning the company from manufacturing, marketing and shipping GenStrip products in regards to a patent infringement claim against the company by J&J. Decision Diagnostics and their subsidiaries appealed the ruling and in May of 2013 the United States Circuit Court restored DECN's ability to manufacture and sell GenStrip. Adding to the good news, the Washington DC U.S. Circuit Court for Federal Claims reversed the ruling made by the Judge in District Court citing the Doctrine of Patent Exhaustion and remanded the case back to the lower court with instructions to use the guidelines set out in the U.S. Circuit Court decision. Keith Berman, the Principal Executive Officer of Decision Diagnostics said of the decision, "The Circuit Court's ruling, reversed a lower court ruling (Northern California) and has put to rest a substantial part of J&J/Lifescan's lawsuit. We are delighted with the ruling. With this court decision, our company can move forward and complete the branding of our GenStrip. By all estimation, November 4 is a seminal day in DECN's history." In essence, this ruling allows DECN to fully implement its rollout strategy for GenStrip.
The Global Diabetic Diagnostic Market was estimated to be around $11.3 billion in 2010 and is expected to grow to $26 billion in 2015 and $32 billion in 2017. This market growth is precipitated by the global growth of diabetes. According to the World Health Organization (WHO), there were 347 million in the world with diabetes in 2012. The International Diabetes Federation believes this number will rise to 552 million in 2030. The Federation goes on to say that in 2011 the cost of diabetes was 11% of total global expenditures at nearly a half a trillion dollars. These market metrics are why incumbent health care companies will vigorously defend their market share positions and why new market entrants are eager to get their products into the market. Just 1% of the expected 2017 market for diabetic diagnostics equates to $320 million in revenues for a company, which is significant to both existing and new companies.
Decision Diagnostics management is confident that they can capture market share with their lower priced, effective GenStrip. Decision Diagnostics has extensive experience as a distributor of diabetes products and GenStrip is their first proprietary product. DECN announced that they began shipping GenStrip through their Pharma Tech Solutions subsidiary on October 25th and the shipments appear to have continued through October 31st the day of the statement. DECN said they made bulk shipments to large box distributors over that period of time. The sales should show up as revenues in DECN's 2013 4th quarter earnings release, which will reflect an important milestone for Decision Diagnostics in monetizing their proprietary product.
Furthermore, Decision Diagnostics received a signed term sheet for a $12.5 million non-dilutive line of credit for the manufacturing of GenStrip. This alleviates the concerns that DECN did not have the balance sheet to peruse the rollout of GenStrip as aggressively as the company would like. The company believes that at peak manufacturing and shipments they can turn their inventory 1.8 times/month, which means this new line of credit will allow DECN to achieve over $250 million in annual sales if the product demand grows to that level. Mr. Berman commented, "Our credit line provides substantial resources for the company to initiate our important, aggressive and revolutionary GenStrip business strategies." This line of credit should close in November, which will allow DECN to begin fulfilling all orders they receive, further boosting the company's revenues.
The events of the last two weeks have cleared the way for DECN to fully implement the sales and marketing strategy for GenStrip. As soon as the line of credit financing closes in the next few weeks, Decision Diagnostics will have everything in place to fully participate in the diabetes diagnostic market place and to carve out market share in this rapidly growing market.
Disclosure: none
This article, complete with technical charts and data is available at:
http://www.biomedreports.com/20131106160649/why-shares-of-zalicus-may-be-ready-to-make-a-big-move.html
Big Screen Entertainment Group Hires NOW CFO as Financial Consultants
LOS ANGELES, CA, Nov 01, 2012 (MARKETWIRE via COMTEX) -- Big Screen Entertainment Group (PINKSHEETS: BSEG) is pleased to announce that it has hired NOW CFO (www.nowcfo.com) to consult and assist BSEG in its financial filings as well as assist management on other operational related matters.
NOW CFO will provide the highest level of expertise in outsourced CFO, Controller services and operational accounting on an interim basis to BSEG. This relationship should accelerate results and achieve strategic objectives for continuing growth and success.
"NOW CFO has already begun working with us on updating our current financials as well as our other filings. We look forward to working with them and their team of experts, with the goal to maximize shareholder value," stated BSEG CEO Kimberley Kates.
BSEG is very busy at this time getting ready for a strong presence at the AFM (American Film Market) to be held October 31-November 7th in Santa Monica, California. The company is bringing six new completed films this year to the market as well as selling a strong library of titles.
BSEG President Patty Stevens added, "Exciting things are happening for Big Screen in 2013. We will keep our shareholders updated as more activities are finalized."
About NOW CFO:
The NOW CFO mission is to provide the highest level of expertise in outsourced CFO and controller services and operational accounting on an interim basis to emerging, mid-market and large companies in order to accelerate results and achieve strategic objectives for sustainable growth and success.
Big Screen Entertainment Group Announces the Highly Anticipated Indie Horror Movie
"I DIDN'T COME HERE TO DIE" Coming to Theaters in October
BEVERLY HILLS, CA, Oct 10, 2012 (MARKETWIRE via COMTEX) -- Big Screen Entertainment Group (PINKSHEETS: BSEG) is pleased to announce that it will represent the highly anticipated horror film, "I DIDN'T COME HERE TO DIE" for international sales starting at the American Film Market held in Santa Monica, CA between October 31 through November 7, 2012 at the Loews Hotel.
Written, directed, and edited by Bradley Scott Sullivan and produced by Kim Waltrip ("Hit And Run"), "I DIDN'T COME HERE TO DIE" is an intelligent story of six young volunteers working on a humanitarian project in the woods. One unfortunate accident triggers a domino effect of shocking, unexpected events.
"This film gives a whole new twist to this urban legend. It is very well made and extremely entertaining. We're thrilled to include this new film in our line-up," said BSEG CEO Kimberley Kates.
Following a series of successful film festival showings, the film has unanimously received a number of rave reviews.
"One of the best horror film debuts since Sam Raimi unleashed THE EVIL DEAD..." - Bloody-Disgusting.com
Level 33 Entertainment, Tugg, Inc. and The Film Group are releasing "I DIDN'T COME HERE TO DIE" in theaters just in time for Halloween. "I DIDN'T COME HERE TO DIE" will be playing a limited theatrical release October 11 through October 24 across North America.
BSEG will hold a screening of "I DIDN'T COME HERE TO DIE" at The American Film Market on October 31, 2012 at 5:00 p.m. at the AMC Santa Monica 5 for international buyers.
Herborium Group Update on the Signed Letter of Intent with China Health Resources Inc.
Due diligence process enters 2nd phase for the sale of up to 100% of Herborium Group is advancing with major progress underway
TEANECK, N.J., March 12, 2012 /PRNewswire via COMTEX/ -- TEANECK, N.J., March 12, 2012 /PRNewswire/-- Herborium Group, Inc. (HBRM.PK), www.herborium.com, is pleased to announce that the Phase 1 of due diligence for the sale of up to 100% interest to China Health Resources Inc (OTCBB:CHRI) has been completed. "We are very pleased with a timely progress of a due diligence and the completion of the First Phase of the process that is the exchange of the confidential information and documentation," stated Dr. Agnes P. Olszewski CEO of Herborium Group.
"As we have stated in our Press Release of 02/24/2012 regarding a signed Letter of Intent with China Health Resource Inc., both parties are highly motivated to complete the process successfully and in a timely fashion while guided by their fiduciary responsibilities. Both parties are truly excited about the opportunity and remain most optimistic of a smooth transaction and final agreement," concluded Dr. Olszewski.
HERBORIUM GROUP Announces Signing the Letter of Intent With China Health Resource Inc. for Possible Acquisition
TEANECK, N.J., Feb. 24, 2012 /PRNewswire via COMTEX/ -- Herborium Group, Inc., (Pink Sheets: HBRM) www.herborium.com, a Botanical Therapeutics? company, announce today signing the Letter of Intent with China Health Resource, Inc (OTCBB.CHRI) for sales of up 100% interest in Herborium.
Dr. Agnes Olszewski, Chairman and CEO of Herborium stated: "We are most excited to confirm that we are negotiating with China Health Resource, Inc. for an acquisition of up to 100% interests in Herborium. Both companies share the mission to bring Botanical Therapeutics? (natural medicinal products) based on modernized Traditional Chinese Medicine to the mainstream of healthcare. The world market for botanical drugs is over $500 billion and the time for this move cannot be better as market and regulatory changes in the healthcare sector create rapid growth opportunities. To take advantage of those changes a complex expertise is necessary and Herborium posses such unique expertise.
"By combining Herborium marketing, clinical and regulatory competencies and its proprietary product portfolio with CHRI manufacturing capabilities, and market access in China we have an opportunity to create a leader in Botanical Therapeutics? sector. We are looking forward to commence the due diligence and negotiation process leading to successful completion of this transaction," concluded Dr. Olszewski.
China Health Resource Reports on Preliminary Record Fourth Quarter and Year-End 2011 Results; Announces 2012 Earnings Guidance
--2011 record breaking sales and earnings well above Company's expectations -- Revenues expected to increase by $24.7 million or 241% year-over-year to $34.9 million -- Net Income expected to total to $6.8 million, or $0.038 per share for 2011 an increase of approx 150% (total shares over 176 million) -- Company announces earnings guidance for 2012 and establishes a range between $0.06 and $0.065 per share
SICHUAN, China, Feb. 16, 2012 /PRNewswire via COMTEX/ -- China Health Resource, Inc. (OTCBB: CHRI News), today announced expected earnings for the fourth quarter and year ended December 31, 2011, subject to the completion of an independent audit. The company expects 2011 fourth quarter operating revenues of more than $12.5 million, an $8.5 million or a 218% increase over the same period in 2010. For the year, the company anticipates reporting operating revenues of $34.9 million, a 241% increase over 2010 revenues of $10.2 million.
The company expects 2011 fourth quarter net income to be $2.7 million, or $0.015 per fully diluted common share, compared with $1.6 million or $0.01 per share for the fourth quarter of 2010. For the year, the company anticipates net income to be $6.8 million, or $0.038 per fully diluted common share, compared with a net income of $2.7 million, or $0.02 per share in the previous year.
The growth is attributed to expansion of the TCM product lines particularly its premier TCM herbs such as Gastrodiae ("TianMa") and improvements in sales channel management for markets outside of the Sichuan province combined with consistent cost controls.
"We are extremely pleased with the solid results for the fourth quarter and the year," said Jiayin Wang, President and CEO of CHRI. "These results are a reflection of the hard work and commitment of China Health Resource's employees to execution of our company's goals. Based on the 2011 results as well as our continued implementation of our strategic goals this year, we look forward to a very successful 2012."
2012 Earnings Guidance
China Health Resource has issued earnings guidance for 2012. The company's 2012 earnings are estimated to be in the range of $0.06 and $0.065 per share. The company's earnings forecasts are subject to numerous risks, including those described under 'Forward-Looking Statements' below and under 'Risk Factors' in its annual and quarterly reports.
"Speaking to the company's focus in 2012," Wang added, "we will continue to maintain our leadership in our DAR franchise while we grow our product lines with valuable and high growth products like Gastrodiae. In addition, we will pursue growth opportunities worldwide through acquisition and distribution and grow in areas where we can best serve customers and create value."
China Health Resource will provide more detailed results in its final 2011 fourth quarter and year-end earnings press release and 10-K filing
I'm a fellow shareholder. I saw that news was not always posted. so I started posting the news so people had an idea of what the company was doing.
China Health Resource Entering USA Markets - Opens Investor Relations and Financial Marketing Office in Princeton NJ
Company attracts renowned NYC media veteran to head strategic Financial Marketing, Investor Relations and domestic acquisitions programs
SICHUAN, China, Feb. 13, 2012 /PRNewswire via COMTEX/ -- China Health Resource, Inc. (OTCBB: CHRI.OB News), today announced that they have opened a Princeton, New Jersey office and have appointed Mr. Steven Weiss, a veteran in financial media to head the company's Investor Awareness program. Mr. Steven Weiss will be heading and putting forward an aggressive Investor Awareness Program along with strategic long term financial marketing incentives and acquisitions.
Mr. Weiss brings to us over 30 years of Financial & Media marketing experience with positions at CBS TV, Viacom and Universal Media Group.
Mr. Weiss stated yesterday, "The enormous growth of China Health Resource and their desire to rapidly expand their product base in the USA attracted me here and I am excited to bring my expertise in all avenues of financial marketing to this very undiscovered and undervalued company. Bringing limelight to the investment community is the first order of business. A sound strategy is the bedrock of any Investor Awareness program and nothing contributes more to its ultimate success. Together with Jiayin Wang, Chairman and CEO of China Health Resource along with his staff, we will build a comprehensive powerhouse of a company.
"With the astronomical rise in USA health care costs, many companies no longer offer their employees major health care insurance or are asking for significant co-payments out of their salaries. We strongly feel that given the correct marketing plan that Traditional Chinese Medicine (TCM) will be a very affordable alternative for Americans on strict budgets due to the severe economic environment. I envision a new foundation built upon educating USA citizens on TCM medications that will not only compete with the big pharmaceutical companies but will be a multi-billion dollar revenue foundation for China Health Resource here in the USA," added Mr. Weiss.
Jiayin Wang, the Chairman and CEO of CHRI says: "We are very proud to announce that Mr. Steven Weiss has been appointed to head our strategic financial marketing and investor relations program in the USA. Mr. Weiss credentials are of great caliber - a true renowned veteran in media and investors relations. We are fortunate to have him join us at this time. He will be immediately directing a comprehensive and aggressive Investor Awareness Program for China Health Resource and create wide awareness of our value proposition and mission."
China Health Resource Announces Investor and Public Awareness Initiative
CHRI Signs Long Term Contract with Major Global News and Media Company
SUINING, China, Feb. 8, 2012 /PRNewswire via COMTEX/ -- China Health Resource, Inc. (OTCBB: CHRI), announced today its plan to launch an aggressive Investors and Public Awareness Campaign throughout 2012. Strategies and programs are designed to increase market awareness of the Company among investors, institutions, and financial analysts. To grow its market presence, the company announced that it has signed a long term contract with a global news and media company as part of this awareness campaign initiative. The company will make further appointments in this area shortly and through 2012.
Jiayin Wang, Chairman and CEO of CHRI stated: "We are most excited to confirm that we now enter our next logical phase in the business - to increase public and investor awareness of CHRI and TCM. We want to articulate our progress but most importantly our vision for alternative healthcare. Our business has grown from a developmental stage and progressing into a growth phase. We have announced our "Go Global 2012" expansion program. We also have announced an acquisition initiative we are actively at. We are now receiving many serious inquires in those areas. We want the public to know more of our unique healthcare products, research but more importantly of our vision for better healthcare and we want this message to reach a global audience. We want to attract people, talent, investors and companies to join us in this major global alternative health care trend. For an aging global population, this is a must".
Traditional Chinese medicine (TCM) pharmaceutical products, along with synthetic western pharmaceuticals, are essential to the central healthcare system in China. The industry has been and is expected to continue growing significantly. In recent years in western countries such as the U.S. and the U.K., awareness of the benefits of TCM products has become increasingly attractive.
"CHRI is capitalizing in the new trend of increased demand for alternative healthcare products from an aging population in the major global economies like USA, Japan, China, Germany and Italy, the general increasing need for healthcare, and the increasing acceptance of alternative and preventive health care worldwide. Financial analysts need to know, investors need to know, the public needs to know. It is our duty to create this awareness. And the more we do, the more everyone benefits especially our shareholders," added Jiayin Wang, the Chairman and CEO of CHRI.
Dirty Love was on Showtime last night
It will be on again Feb 17, 22 and 28
just for info.
Did not notice if anything else was playing.
/C O R R E C T I O N -- China Health Resource, Inc./
SUINING, Sichuan, Jan. 24, 2012 /PRNewswire via COMTEX/ -- In the news release, China Health Resource Signs Two New Agreements for the Sale of Gastrodia Valued At $1.07 Million USD, issued 24-Jan-2012 by China Health Resource, Inc. over PR Newswire, we are advised by the company that the first paragraph, first sentence, should read "China Health Resource, Inc. (OTCBB: CHRI.OB News), announced today that it has signed two new agreements for the sale of Gastrodia valued at 67.5 Million RMB or approximately $10.7 Million USD" rather than "China Health Resource, Inc. (OTCBB: CHRI.OB News), announced today that it has signed two new agreements for the sale of Gastrodia valued at 67.5 RMB or approximately $1.07 million USD" as originally issued inadvertently. In addition, the headline should read, "China Health Resource Signs Two New Agreements for the Sale of Gastrodia Valued At $10 Million USD" rather than "China Health Resource Signs Two New Agreements for the Sale of Gastrodia Valued At $1.07 Million USD" The complete, corrected release follows:
China Health Resource Signs Two New Agreements for the Sale of Gastrodia Valued At $10 Million USD Sales Continue to Grow for CHRI as the Leading Distributor of Pharmaceutical Grade Gastrodia In China
China Health Resource, Inc. (OTCBB: CHRI.OB News), announced today that it has signed two new agreements for the sale of Gastrodia valued at 67.5 Million RMB or approximately $10.7 Million USD. The agreements are with Chongqing Valley Pharm Corp and Sichuan Zhiyuanguanghe Pharm Corp and provide for a combined purchase total of 550 tons of Gastrodia from January 1, 2012 to December 31, 2012.
CHRI recently signed a 3 year exclusive agreement with a leading producer of Gastrodia in Pingwu, Sichuan. The quality of Gastrodia under this supply agreement is expected to meet the latest formal TCM pharmaceutical standard and gives CHRI continued leverage in the Traditional Chinese Medicine (TCM) marketplace in China, as the main controlling distributor and supplier of pharmaceutical grade Gastrodia (also known as Tianma).
"Demand is high for pharmaceutical grade Gastrodia and the company expects both our Gastrodia product revenues and bottom line will surpass last year. We have started the new year with strong demand aided by our brand recognition and high quality GAP standards," stated Jiayin Wang, Chairman and CEO of CHRI.
Gastrodia is recognized as one of the higher value herbs in TCM.
"We have announced continuous record growth for 2011 and anticipate continued double-digit growth for Gastrodia product line in 2012. We anticipate another record breaking year in our revenues and profits," says Weihai Liu, CFO of CHRI.
"In addition to great opportunities for Gastrodia, Dahurian Angelica (DAR) is successfully established as a franchise. With our Dragonhead Enterprise status, which confirms CHRI as a quality-oriented government sanctioned enterprise, we are positioned for a large scale global market penetration for CHRI's products," says Jiayin Wang.
China Health Resource Signs Two New Agreements for the Sale of Gastrodia Valued At $1.07 Million USD
Sales Continue to Grow for CHRI as the Leading Distributor of Pharmaceutical Grade Gastrodia In China
SUINING, Sichuan, Jan. 24, 2012 /PRNewswire via COMTEX/ -- China Health Resource, Inc. (OTCBB: CHRI.OB News), announced today that it has signed two new agreements for the sale of Gastrodia valued at 67.5 RMB or approximately $1.07 million USD. The agreements are with Chongqing Valley Pharm Corp and Sichuan Zhiyuanguanghe Pharm Corp and provide for a combined purchase total of 550 tons of Gastrodia from January 1, 2012 to December 31, 2012.
CHRI recently signed a 3 year exclusive agreement with a leading producer of Gastrodia in Pingwu, Sichuan. The quality of Gastrodia under this supply agreement is expected to meet the latest formal TCM pharmaceutical standard and gives CHRI continued leverage in the Traditional Chinese Medicine (TCM) marketplace in China, as the main controlling distributor and supplier of pharmaceutical grade Gastrodia (also known as Tianma).
"Demand is high for pharmaceutical grade Gastrodia and the company expects both our Gastrodia product revenues and bottom line will surpass last year. We have started the new year with strong demand aided by our brand recognition and high quality GAP standards," stated Jiayin Wang, Chairman and CEO of CHRI.
Gastrodia is recognized as one of the higher value herbs in TCM.
"We have announced continuous record growth for 2011 and anticipate continued double-digit growth for Gastrodia product line in 2012. We anticipate another record breaking year in our revenues and profits," says Weihai Liu, CFO of CHRI.
"In addition to great opportunities for Gastrodia, Dahurian Angelica (DAR) is successfully established as a franchise. With our Dragonhead Enterprise status, which confirms CHRI as a quality-oriented government sanctioned enterprise, we are positioned for a large scale global market penetration for CHRI's products," says Jiayin Wang.
China Health Resource Signs 3 Year Exclusive Agreement for Acquisition of Gastrodia Extending Very Successful Product Line Through 2015
SHANGHAI, Jan. 20, 2012 /PRNewswire via COMTEX/ -- China Health Resource, Inc. (OTCBB: CHRI), announced today that the company has signed a 3 year exclusive agreement with a leading producer of Gastrodia in Pingwu, Sichuan. This exclusive contract term is from April 1, 2012 to March 31, 2015, and extends the very successful product line for an additional 3 years from the prior agreement which will end March 31, 2012. The quality of Gastrodia under this agreement is expected to comply to the latest formal TCM pharmaceutical standard and will give CHRI continued leverage in the Traditional Chinese Medicine (TCM) marketplace in China, as the main controlling distributor and supplier of pharmaceutical grade Gastrodia (also known as Tianma).
Widely recognized for producing high-quality Angelica, CHRI is expanding its TCM offerings with a highly regarded and marketable TCM herb, commonly known as Tianma in China. Pure Gastrodia in Pingwu County of the Sichuan Province contains a high content of active ingredients, with low heavy metal content. Free of pollution and boasting high quality, the demand in the market for pure Gastrodia surpasses the supply in Pingwu County.
"This exclusive agreement adds a stable high quality source of supply of our new flagship product, Gastrodia. Gastrodia demand is large and supply of pure Gastrodia of consistent quality is hard to find. Having established our leading position in pharmaceutical Dahurian Angelica Root (DAR), allows us to attract high quality supply of key herbs which used with our standards can command higher prices for CHRI as well as our suppliers." stated Jiayin Wang, Chairman and CEO of CHRI.
The company already started its General Agricultural Process (GAP) standard implementation for Gastrodia. With standards in place, the quality can be properly managed and controlled. This is considered by many experts as an essential step in the modernization of Traditional Chinese Medicine (TCM) products.
"CHRI is committed to establishing and promoting standards of raw herbs and TCM products. GAP DAR is now well accepted as the standard for pharmaceutical grade DAR in China and providing stable revenues and margins to CHRI. Gastrodia commands a larger market with high margins. Gastrodia in 2011 has grown its sales in double-digits. We expect the Gastrodia product line to continue to add significant revenue and earnings for many years." added Jiayin Wang.
Gastrodia has large demand in China and Asia and further potential with the demands created from new alternative health products worldwide, general growing aging population and the imminent need to find alternative health solution with less side effects. Gastrodia currently retails for about 250~1,000 Yuan/kg (US$38~150/kg). It is considered one of China's highest priced TCM drugs available in the market.
China Health Resource Pharmaceutical Grade Gastrodia Product Line Expected to Contribute $8 Million in Revenue to 2011 Year End
Strength of Core Product Lines and New High Margin Products Expected to Drive Record Revenue and Earnings
SHANGHAI, Jan. 19, 2012 /PRNewswire via COMTEX/ -- China Health Resource, Inc. (OTCBB: CHRI), announced today that its pharmaceutical grade Gastrodia based product line has experienced double digit sales growth in 2011 with increased profit margins. The Gastrodia product line is expected to generate an estimated 50 million yuan (US$8 million) of revenue in 2011 for CHRI. The strength of the Company's core product lines and rapid growth in newer higher margin products is expected to drive record revenue and earnings. The Company will confirm the disclosed preliminary figures at the time of disclosure of the annual report for 2011.
China Health Resource, Inc. entered into an exclusive agreement with a leading producer of Gastrodia in Pingwu, Sichuan in April 2011. The agreement gives CHRI leverage in the Traditional Chinese Medicine (TCM) marketplace in China, as the main controlling distributor and supplier of Gastrodia (also known as Tianma). Gastrodia currently retails for about 250~1,000 yuan/kg (US$38~150/kg) and is considered one of China's highest value TCM drugs available in the market. This exclusive arrangement for the supply of Gastrodia is expected to generate an estimated combined total of 50 million yuan (US$8 million) of revenue for CHRI over the 2011-2012 period.
"Our core strength in establishing DAR as a standard has resulted in an enviable growth in revenues and margins in our DAR product line and the Gastrodia product line is the natural progression of CHRI product on large global markets with higher profit margins. We expect this will be reflected in our 2011 year in both revenues and earnings" stated Jiayin Wang, Chairman and CEO of CHRI.
"Gastrodia is an important herb with high margins and we expect it will add a significant contribution to our top and bottom line. As a TCM ingredient, it has pain relieving and anti-inflammatory properties, and it is used in the treatment of severe headaches and nervous fatigue. In time, we expect Gastrodia to have the same standard of acceptance as GAP DAR." added Jiayin Wang.
China Health Resource (CHRI) CEO Delivers Speech to the 17th People's Congress of Pingwu, Sichuan
Keynote message focused on the essential role of GAP standards in expanding the global market for herbs such as Gastrodia in healthcare
SHANGHAI, Jan. 12, 2012 /PRNewswire via COMTEX/ -- Jiayin Wang, Chairman and CEO of China Health Resource, Inc. (OTCBB: CHRI.OB News), announced today he has been elected as representative member to the 17th People's Congress of Pingwu County in Sichuan, People's Republic of China where he delivered a speech to Congress.
Jiayin Wang's speech was focused on the strategic goals the government should adopt in order to support and encourage businesses to make herbal medicines using GAP standards and creating rich quality brands. "So that herbal healthcare products out of China can benefit the world and also reward those who make investment in this area," says Mr. Jiayin Wang during his speech to the People's Congress.
Jiayin Wang has been the People's Senator of Suining City, Sichuan Province, People's Republic of China ("PRC") since 1995. He has been 12 consecutive time recipient for the national award in the People's Republic of China. In 2006, he received the China's 500 Great Entrepreneurs Award given by the President of the People's Republic of China. Wang has served as President and Chairman of the Board of Directors of Sichuan Yinfa Resource Development Co., Ltd., an affiliate of CHRI, where he spearheaded the development of the standardization of pharmaceutical grade Dahurian Angelica Root (DAR) under the Chinese State Food and Drug Administration Good Agricultural Practice (GAP) of Medical Plants and Animals. Additionally, he has been the Chairman of Sichuan Province DAR Association since 2001.
China Health Resource , Inc. (CHRI) is the leading provider of GAP quality DAR in the People's Republic of China (PRC) under the registered Trademark Chuan Baizhi(TM) The company strives at modernizing Traditional Chinese Medicine (TCM) and is now extending its GAP DAR know-how to other TCM herbs.
CHRI, who successfully pioneered and commercialized GAP Dahurian Angelica Root (DAR), is providing its expertise in implementing General Agricultural Practices (GAP) to Gastrodia.
"Gastrodia is considered one of the higher valued herbs in TCM, currently retailing for about 250~1,000 yuan/kg (US$38~150/kg). Pingwu Gastrodia is known for its high purity and efficacy. Our objective at CHRI is to commercialize Gastrodia in the most pure form and using GAP standards as we did with GAP DAR. Unlike other herbs, Gastrodia is a tuber that grows best under clean environmental conditions, free from pollutants, and most importantly within given altitude," said Yi Peng, Deputy General Manager, who has been involved in GAP implementation starting with GAP DAR.
China Health Resource CEO Delivers Speech at 10th Year Anniversary Celebration
Keynote message focused on the role of CHRI and GAP standards in modernizing TCM beyond China.
SHANGHAI, Jan. 11, 2012 /PRNewswire via COMTEX/ -- Jiayin Wang, Chairman and CEO of China Health Resource, Inc. (OTCBB: CHRI), delivers the keynote speech for the 10th year Anniversary Celebration at Suining Yinfa DAR Industrial Co, Ltd, wholly owned subsidiary (Yinfa). Wang quotes in speech Robert Johnson, founder of Johnson & Johnson and Pfizer as major inspirations and corporate models.
"10 years ago, we ventured into an industry suffering from antiquated technology, know-how and ancient beliefs. Starting a new business with new procedures and trying to change old traditions with history that dates as far back as 1,000 years was a daunting task," said Jiayin Wang, Founder, Chairman and CEO of CHRI and Chairman of Suining DAR Association. The DAR Association is a cooperative of over 100,000 farmers of Dahurian Angelica Root (DAR) pooling their collective resources to provide economic and productivity benefits to its farmer members.
Jiayin Wang is a 12 consecutive time recipient for the national award in the People's Republic of China. In 2006, he received China's 500 Great Entrepreneurs Award given by the President of the People's Republic of China. Wang has served as President and Chairman of the Board of Directors of Sichuan Yinfa Resource Development Co., Ltd., an affiliate of CHRI, where he spearheaded the development of the standardization of pharmaceutical grade Dahurian Angelica Root (DAR) under the Chinese State Food and Drug Administration Good Agricultural Practice (GAP) of Medical Plants and Animals. Additionally, Wang has been the People's Senator of Suining City, Sichuan Province and the People's Republic of China ("PRC") since 1995 and the Chairman of Sichuan Province DAR Association since 2001.
China Health Resource, Inc. which operates through its wholly own subsidiary Yinfa, is the leading provider of GAP quality DAR in the People's Republic of China (PRC) under the registered Trademark Chuan Baizhi(TM). The company strives at modernizing Traditional Chinese Medicine (TCM) and is now extending its GAP DAR know-how to other TCM herbs. TCM is listed in China's strategic current 5-Year Plan to be an important area for development, specific areas are research and development for new cures using TCM, modernization of TCM and development of new health products. The industry of TCM in China is growing considerably compared to other segments of the healthcare industry and is expected by many experts to continue also worldwide given by the long trends in demand for alternative health care, aging population and demand for health product of pure natural basis with less side effects.
"We had to discover new means and deal with many different groups many with contradictory views, groups including pharmaceutical giants, government, academicians, and farmers. The beginning was not easy," says Jiayin Wang.
"I was inspired back then by Robert W. Johnson, founder of Johnson & Johnson, who inspired by a speech by an antiseptic advocate, innovated and rejuvenated an old industry and changed how cuts and wounds would be treated from the surgery room to the home to the major success of the famous Band-Aid," added Jiayin Wang in his 10th Year Anniversary speech.
"The company began from humble beginnings and significant challenges after now 10 years of work, we have standardized BaiZhi (Dahurian Angelica Root or DAR) using the General Agricultural Process (GAP) international standard. We will continue now with other important herbs. We already started with GAP for Gastrodia Rhizoma ("Tian Ma") as our next standard. We are now a nationally accredited enterprise - A Dragonhead enterprise, giving us a high degree of governmental level certification as a quality company in China meeting strict standards," says Mr. Wang summarizing some of the significant milestones achieved.
"We also have grown financially in the recent years and this is important for our shareholders and employees and expect to continue doing that. We are adding new products like Gastrodia which have a higher profit margin and is a larger demand market," continues Mr. Wang.
The company announced robust record breaking quarterly earnings for the 3rd Quarter 2011. CHRI reported over $9.3 million in revenues and $1.8 million in net income, a 219% increase in revenues and a 141% increase in profits from the third quarter of 2010. This translates to earnings of about $0.03 per share for the first three quarters of 2011. The net earnings performance in the first three quarters has already exceeded the net profit for the entire year of 2010 by 61%.
"CHRI was able to keep its accelerated growth rate and achieved excellent results in the year even though the general market for pharmaceutical products in China had a slower year. Orders in the 3rd quarter were up more than double comparing to the same period of last year, with an increased net margin from 17% to 20%," said Weihai Liu, CHRI's CFO. "
"2011 and our first 10 Years has been hard work yet rewarding. From here forward we have to have a keen focus in our mission: We must continue establishing standards and continue modernizing TCM for its wider market penetration, select niche products with good margins and going global - all these are important to maintain in our minds as commitments at all times," said Mr. Wang with great emphasis addressing his audience which included many senior management of the company.
"Sichuan Bazhi DAR is now a strong franchise. While we continue with Gastrodia, an important note on going global, I have been further inspired recently with the Pfizer, a multinational pharmaceutical company, and of their initial success, later challenges and later growth through mergers and acquisition. Pzifer was an innovator in fermentation of sugar using a fungus and later used it's know-how to mass produce penicillin for World War II in the United States. Without their knowledge in fermentation, many USA soldier and allies would not have received proper antibiotic medication. And later in the 1990's, Pfizer grew rapidly by gaining wider market distribution for its products, and more unique technology through mergers and acquisitions however above all they gained superior talent," says Wang in his speech.
"We know the area of mergers and acquisition especially outside of China is new. We also know we have unique challenges that other places do not have in the world. Our currency, the Renminbi and capital in general is under strict foreign currency control and also traveling for our managers is not easy, however just like we learned to work hard and reap the rewards later, we have learned to adapt, improve and succeed at hard tasks especially when there is a grand cause. This and what our company is all about is a grand cause. It benefits people worldwide and shareholders as well. I thank all of you, our shareholders, consultants, and wish you every success for our next 10 years," Mr. Wang said in very high spirited words.
China Health Resource Passes Major Provincial Inspection
Chuan DAR Project inspection passes with flying colors
SICHUAN, China, Dec. 8, 2011 /PRNewswire via COMTEX/ -- China Health Resource, Inc. (OTCBB: CHRI), through its wholly owned subsidiary Suining Yinfa DAR Industrial Co, Ltd (Yinfa), the only the provider of pharmaceutical GAP quality DAR in the People's Republic of China under the registered Trademark Chuan Baizhi(TM), announces it has passed a major provincial inspection by the Sichuan Province Agricultural Department.
"This is a major step for the company in ensuring the company's commitment to setting the highest quality standard for the TCM pharmaceutical industry," said Jiayin Wang, Chairman and CEO of CHRI.
The inspection was headed by the Director of Sichuan Provincial Agricultural Department, Mr. Yongchang Ren who inspected the status of the "Chuan DAR" industrialization project carried out by Yinfa.
CHRI's CEO Jiayin Wang and senior staff presented a comprehensive report on the major project undertaken by the company's subsidiary Yinfa to Mr. Ren. The report included the following 6 categories:
Improved management of City's planting area and increase in the company sales
Improvement of local TCM farmers' income
Completion of R&D Products
Completion of technical and DAR projects
Increase in company's intellectual property rights
Flourishing of Farmer's DAR Association
Director Ren gave high recognition on the company's recent year's achievements, and encouraged the company to maintain its newly acquired Dragonhead Enterprise status which grants certain government support such as reduced taxation. Director Ren advised CHRI's management to keep good development momentum and to continue leading the mass TCM farmers towards a better life. Mr. Ren said to the company that it should focus more on making high quality and branded products.
also, from the quarterly
In addition, Big Screen now has access to over 300 film titles to put through its VOD deal
with various outlets through its relationship with Allied Entertainment for certain
territories both internationally and domestically.
China Health Resource Receives Letter of Intent for DAR Totaling About $8 Million
SICHUAN, China, Dec. 6, 2011 /PRNewswire via COMTEX/ -- China Health Resource, Inc. (OTCBB: CHRI), through its wholly owned subsidiary Suining Yinfa DAR Industrial Co, Ltd (Yinfa), announced today that it has received 2 new Daharian Angelica Root (DAR) purchasing Letter of Intents (LOI) which totals to over 50 million RMB (approximately US$8 Million).
The LOI were the result of the Company's participation at the 13th West China International Exhibition (CIE) Fair held at Chengdu, Sichuan where CHRI participated with 4,564 other companies and intense follow up. "We are pleased with this LOI and also being Dragonhead Enterprise which allows recognition and access to important events and to government officials," said Mr. Jiayin Wang, Chairman and CEO of CHRI.
CHRI, through its subsidiary Yinfa, participated in the exhibition under the special designation of a provincial agricultural Dragonhead Enterprise. CHRI participates in this event representing the only GAP DAR under the Chuan Baizhi(TM) national trademark in China.
China Health Resource Completes Key Research Project - New Proprietary Product Lines
Completion and acceptance of strategic research project with major TCM University and Research Institute: New Proprietary Products Added to Pipeline
SHANGHAI, Dec. 5, 2011 /PRNewswire via COMTEX/ -- China Health Resource, Inc. (OTCBB: CHRI), through its wholly owned subsidiary Suining Yinfa DAR Industrial Co, Ltd (Yinfa), the leader in GAP standard for Dahurian Angelica Root (DAR) in the People's Republic of China under the registered Trademark Chuan Baizhi(TM), announces completion of key scientific research project in collaboration with Chengdu Chinese Traditional Medicine & Science University (Chengdu TCM University) and the Sichuan Chinese Medicine Research Institute (Medicine Institute).
This research addresses innovative products in the areas of cough, diabetes, headaches, and chronic fatigue OTC and TCM pharmaceuticals. "We expect to announce some of the products addressed by this research regarding clinical trials and other commercial phases of development next," said Jiayin Wang, Chairman and CEO of CHRI.
Traditional Chinese medicine (TCM) pharmaceutical products, along with western pharmaceuticals, are essential to the central healthcare system in China. The industry has been and is expected to continue growing significantly. In recent years in western countries such as the U.S., awareness of the benefits of TCM products has become increasingly attractive.
"This research is key for the company's growth strategy as we become a more vertically integrated company in the near future. It allows us to maintain a strong competitive edge by managing the rare supply of pharmaceutical grade ingredients and it provides management direction for the effective deployment of our capital and resources in a manner that brings short and longer terms investment results," said Jiayin Wang, Chairman and CEO of CHRI. "The TCM pharmaceutical industry is highly fragmented especially in China and standards are needed to safeguard quality. Our early investment and major commitment in GAP standard DAR has resulted in a successful project with scientific discoveries which will increase our business significantly. We at CHRI are committed to establishing GAP standards to major TCM herbs for pharmaceutical use. CHRI is dedicated to this mission," added Mr. Wang.
The research project, which was formally started in April 2008, covered research related to DAR, Frictillaria, Berberine and other TCM herbs considered by company and industry experts to address major healthcare problems. The research included studies such as "Study of Primary Processing of Angelica Dahurian", "Establishment of Evaluation System for Angelica Dahurian Quality", "Study on Obtaining Effective Ingredients in Angelica Dahurian", "Development of New Headache Medicine in Tablets", "Research and Development of Angelica Dahurian (DAR) for Heath Care and Related Products" and others. These studies use DAR as a key ingredient in combination with other natural herbs. DAR is known for its properties to treat pain, swelling and pustule.
The research was supported by government grants and the intellectual property and commercial rights belongs to the company. The project incurred total expense of 37.5 million RMB. The research by Yingfa, Chengdu TCM University and the Medicine Institute had received Governmental Research Support Grant of 4.2 million RMB. The Company contributed capital and our GAP DAR expertise. CHRI matched with as high as 4.1 million RMB. The project report and results were officially accepted in the presence of a group of evaluating government specialists at the Provincial Bureau of Technology.
"We are very excited at the completion of this research project and thankful to our partners Chengdu TCM University and the Medicine Institute for their full cooperation. The level of scientific expertise in the TCM field was shown to be of the highest caliber and the results speak for themselves. This research will result in enhancing many of our existing products and more importantly provide the company with new proprietary products that can address health related ailments in more effective ways than at present adding to our competitive edge in the market," said Jiayin Wang, Chairman and CEO of CHRI.
China Health Resource Goes Global
Acquisition, Distribution and Joint Ventures plans for 2012 and beyond
SHANGHAI, Nov. 29, 2011 /PRNewswire via COMTEX/ -- China Health Resource, Inc. (OTCBB: CHRI), through its wholly owned subsidiary Suining Yinfa DAR Industrial Co, Ltd (Yinfa), announces it active participation at "HOW TO BECOME A GLOBAL COMPANY NOW THROUGH ACQUISITION! Business and Legal Strategies for Chinese Companies Going Global" sponsored by Boss & Young, EvoTech Management Corporation and Loeb & Loeb LLP, a seminar held in Shanghai, PRC.
"Going global is in our next growth strategy for 2012," said Jiayin Wang, Chairman and CEO of CHRI, "and acquisitions will accelerate the manner in which we can grow our TCM platform quickest."
The company recently reported its financials with over $9.3 million in revenues and $1.8 million in net income, a 219% increase in revenues and a 141% increase in profits from the third quarter of 2010. The net earnings performance in the first three quarters has already exceeded the net profit for the entire year of 2010 by 61%.
"We have built a strong franchise base with GAP standard Chuan DAR and as evidenced by our financial growth and performance reflecting it. TCM is proving to be one of the new growth segments within the pharmaceutical industry not only in China but globally, and we believe TCM requires international standards such as GAP in order to develop into a matured industry to solidify the acceptance of TCM world-wide. The Chuan DAR and GAP standard for DAR and other TCM products are our core contribution to the TCM industry. It is time to expand our business globally, and we will be seeking global partners to do so," said Jiayin Wang.
TCM is considered one of the fastest growing segments of the healthcare industry within China and Asia. In developed countries, TCM is also gaining pace establishing its role as an alternative medicine practice as medical and pharmaceutical companies look for new and more cost effective products. TCM, where appropriate, is considered in applicable cases recognized to be of a lower cost, more natural solution and with significantly less side effects than chemical drug products.